Microbot Medical Announces Notice of Intention to Grant of European Patent for Adjustable Guidewire Technology
March 04 2019 - 8:07AM
Further expanding its global IP portfolio, Microbot Medical Inc.
(Nasdaq CM: MBOT) received an official communication from the
European Patent Office regarding its intention to grant European
Patent Application No. 13 746 563, which covers an adjustable
guidewire for use in percutaneous coronary artery disease
procedures. Consistent with its growth strategy, the Company will
continue to invest in expanding its IP portfolio and strengthening
its assets to maintain a sustainable competitive advantage for its
technology platforms.
“As pioneers in the micro-robotic medical space,
it is extremely encouraging to see that global regulatory bodies
continue to recognize and provide protections for our novel
technologies,” commented Harel Gadot, CEO, President and
Chairman. “We believe these significant barriers to entry
provide us with protections as we continue to monetize our
investments and maximize shareholder value. Our strategic decision
to acquire CardioSert™ and its adjustable guidewire technology is
bearing fruit and represents a major opportunity for us as we are
aiming to obtain a leadership position in the micro-robotic
endo-luminal space.”
Including this latest notification, the Company
has 31 issued/allowed patents and 20 patent applications pending
worldwide.
About Microbot Medical,
Inc.
Microbot™, which was founded in 2010 and
commenced operations in 2011, became a NASDAQ listed company on
November 28, 2016. The Company specializes in transformational
micro-robotic medical technologies leveraging the natural and
artificial lumens within the human body. Microbot’s current
technological platforms, ViRob™, TipCAT™ and CardioSert™, are
comprised of three highly advanced technologies, from which the
Company is currently developing its first product candidate: The
Self-Cleaning Shunt, or SCS™, for the treatment of hydrocephalus
and Normal Pressure Hydrocephalus, or NPH. The Company also is
focused on the development of a Multi Generation Pipeline Portfolio
(MGPP) utilizing all technologies. Further information about
Microbot Medical is available at
http://www.microbotmedical.com.
The ViRob™ technology is a revolutionary
autonomous crawling micro-robot which can be controlled remotely or
within the body. Its miniature dimensions allow it to navigate
and crawl in different spaces within the human body, including
blood vessels, the digestive tract and the respiratory
system. Its unique structure gives it the ability to move in
tight spaces and curved passages as well as the ability to remain
within the human body for prolonged time. To learn more about
ViRob™ please visit
http://www.microbotmedical.com/technology/virob/.
TipCAT™ is a transformational self-propelled,
flexible, and semi-disposable locomotive device providing see &
treat capabilities within tubular lumens in the human body such as
the colon, blood vessels, and the urinary tract. Its
locomotion mechanism is perfectly suitable to navigate and crawl
through natural & artificial tubular lumens, applying the
minimal necessary pressure to achieve the adequate friction
required for gentle, fast, and safe advancement within the human
body. To learn more about TipCAT™, visit
http://www.microbotmedical.com/technology/tipcat/.
CardioSert™ technology contemplates a unique
combination of a guidewire and microcatheter, technologies that are
broadly used for endoluminal surgery. The CardioSert™ technology
features unique steering and stiffness control capabilities, and it
was originally developed to support interventional cardiologists in
crossing the most complex lesions called chronic total occlusion
(CTO) during percutaneous coronary intervention (PCI) procedures
and has the potential to be used in other spaces and applications,
such as peripheral intervention, neurosurgery and urology.
CardioSert™ was part of a technological incubator supported by the
Israel Innovation Authorities (formerly known as the Office of the
Chief Scientist, or OCS), and its device has successfully completed
pre-clinical testing.
Safe Harbor
Statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects” and “estimates”) should also be considered
to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation,
risks inherent in the development and/or commercialization of
potential products, the outcome of its studies to evaluate the SCS
and other existing and future technologies, uncertainty in the
results of pre-clinical and clinical trials or regulatory
approvals, need and ability to obtain future capital, maintenance
of intellectual property rights, and the outcomes with respect to
any litigation the Company is involved in from time to time
(including the success of any appeals). Actual results may differ
materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the businesses of Microbot Medical Inc.
particularly those mentioned in the cautionary statements found in
Microbot Medical Inc.’s filings with the Securities and Exchange
Commission. Microbot Medical disclaims any intent or obligation to
update these forward-looking statements.
Investor Contact: Michael Polyviou EVC Group
mpolyviou@evcgroup.com 732-933-2754
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Apr 2023 to Apr 2024